Izelle Labuschagne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3156715/publications.pdf

Version: 2024-02-01

201674 161849 3,192 63 27 54 citations h-index g-index papers 66 66 66 4222 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Resting-state neuroimaging in social anxiety disorder: a systematic review. Molecular Psychiatry, 2022, 27, 164-179.	7.9	31
2	Is resting-state functional connectivity altered in regular cannabis users? A systematic review of the literature. Psychopharmacology, 2022, 239, 1191-1209.	3.1	5
3	Empirical evidence for cognitive subgroups in body dysmorphic disorder. Australian and New Zealand Journal of Psychiatry, 2021, 55, 381-390.	2.3	2
4	Sex differences in the neuroanatomy of alcohol dependence: hippocampus and amygdala subregions in a sample of 966 people from the ENIGMA Addiction Working Group. Translational Psychiatry, 2021, 11, 156.	4.8	30
5	Identity and shame in body dysmorphic disorder as compared to obsessive-compulsive disorder. Journal of Obsessive-Compulsive and Related Disorders, 2021, 31, 100686.	1.5	9
6	Age Differences in Emotion Regulation and Facial Muscle Reactivity to Emotional Films. Gerontology, 2020, 66, 74-84.	2.8	8
7	Delusional themes in Body Dysmorphic Disorder (BDD): Comparisons with psychotic disorders and non-clinical Controls. Psychiatry Research, 2020, 284, 112694.	3.3	12
8	Task characteristics influence facial emotion recognition age-effects: A meta-analytic review Psychology and Aging, 2020, 35, 295-315.	1.6	66
9	An introductory guide to conducting the Trier Social Stress Test. Neuroscience and Biobehavioral Reviews, 2019, 107, 686-695.	6.1	60
10	MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1. Brain, 2019, 142, 1876-1886.	7.6	114
11	Intranasal oxytocin alters amygdala-temporal resting-state functional connectivity in body dysmorphic disorder: A double-blind placebo-controlled randomized trial. Psychoneuroendocrinology, 2019, 107, 179-186.	2.7	11
12	Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntington's Disease. Journal of the International Neuropsychological Society, 2019, 25, 453-461.	1.8	6
13	The relationship between episodic future thinking and prospective memory in middle childhood: Mechanisms depend on task type. Journal of Experimental Child Psychology, 2019, 178, 198-213.	1.4	11
14	Intranasal oxytocin does not reduce age-related difficulties in social cognition. Hormones and Behavior, 2018, 99, 25-34.	2.1	25
15	Emotion processing in persons who respond vicariously towards others in pain: Disinhibited left-lateralized neural activity for threatening expressions. Laterality, 2018, 23, 184-208.	1.0	2
16	Decision-making, somatic markers and emotion processing in opiate users. Psychopharmacology, 2018, 235, 223-232.	3.1	5
17	Oxytocin selectively modulates brain processing of disgust in Huntington's disease gene carriers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 11-16.	4.8	23
18	Intranasal oxytocin reduces heart rate variability during a mental arithmetic task: A randomised, double-blind, placebo-controlled cross-over study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 408-415.	4.8	24

#	Article	IF	Citations
19	Brain Regions Showing White Matter Loss inÂHuntington's Disease Are Enriched for Synaptic and Metabolic Genes. Biological Psychiatry, 2018, 83, 456-465.	1.3	79
20	F45â€Apathy associated with impaired recognition of happy facial expressions in huntington's disease. , 2018, , .		0
21	Working Memory-Related Effective Connectivity in Huntington's Disease Patients. Frontiers in Neurology, 2018, 9, 370.	2.4	12
22	The relationship between body dysmorphic disorder and obsessive-compulsive disorder: A systematic review of direct comparative studies. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1030-1049.	2.3	22
23	Oxytocin and brain activity in humans: A systematic review and coordinate-based meta-analysis of functional MRI studies. Psychoneuroendocrinology, 2018, 96, 6-24.	2.7	92
24	Testing a longitudinal compensation model in premanifest Huntington's disease. Brain, 2018, 141, 2156-2166.	7.6	33
25	Diminished facial EMG responses to disgusting scenes and happy and fearful faces in Huntington's disease. Cortex, 2018, 106, 185-199.	2.4	10
26	Brief Report: The Impact of Sensory Hypersensitivity and Intolerance of Uncertainty on Anxiety in Williams Syndrome. Journal of Autism and Developmental Disorders, 2018, 48, 3958-3964.	2.7	17
27	Visual scanning of the eye region of human faces predicts emotion recognition performance in Huntington's disease Neuropsychology, 2018, 32, 356-365.	1.3	7
28	White matter predicts functional connectivity in premanifest Huntington's disease. Annals of Clinical and Translational Neurology, 2017, 4, 106-118.	3.7	38
29	Beyond emotion recognition deficits: A theory guided analysis of emotion processing in Huntington's disease. Neuroscience and Biobehavioral Reviews, 2017, 73, 276-292.	6.1	32
30	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
31	Sex-specific effects of intranasal oxytocin on thermal pain perception: A randomised, double-blind, placebo-controlled cross-over study. Psychoneuroendocrinology, 2017, 83, 101-110.	2.7	15
32	The neurobiology of body dysmorphic disorder: A systematic review and theoretical model. Neuroscience and Biobehavioral Reviews, 2017, 83, 83-96.	6.1	38
33	Impairments in Spatiotemporal Gait Adaptation During Obstacle Navigation in Huntington's Disease. Neurorehabilitation and Neural Repair, 2017, 31, 934-943.	2.9	2
34	Abnormal Visual Scanning of Emotionally Evocative Natural Scenes in Huntington's Disease. Frontiers in Psychology, 2017, 8, 405.	2.1	1
35	Families Affected by Huntington's Disease Report Difficulties in Communication, Emotional Involvement, and Problem Solving. Journal of Huntington's Disease, 2017, 6, 169-177.	1.9	13
36	Decision-making ability in current and past users of opiates: A meta-analysis. Neuroscience and Biobehavioral Reviews, 2016, 71, 342-351.	6.1	71

#	Article	IF	Citations
37	The Wisdom to Know the Difference. Psychological Science, 2016, 27, 1651-1659.	3.3	145
38	M5â€Neural networks linked to emotion processing modulated by intranasal oxytocin in huntington's disease gene-carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A103.1-A103.	1.9	0
39	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. Journal of the International Neuropsychological Society, 2016, 22, 595-608.	1.8	44
40	Improving Research Standards to Restore Trust in Intranasal Oxytocin. Biological Psychiatry, 2016, 79, e53-e54.	1.3	14
41	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine, 2015, 2, 1420-1429.	6.1	122
42	Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. Frontiers in Human Neuroscience, 2015, 9, 634.	2.0	8
43	Effects of oxytocin and genetic variants on brain and behaviour: Implications for treatment in schizophrenia. Schizophrenia Research, 2015, 168, 614-627.	2.0	44
44	Differential effects of social stress on laboratory-based decision-making are related to both impulsive personality traits and gender. Cognition and Emotion, 2015, 29, 1475-1485.	2.0	12
45	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia, 2015, 79, 138-146.	1.6	56
46	Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 39-47.	10.2	112
47	Oxytocin Modulation of Amygdala Functional Connectivity to Fearful Faces in Generalized Social Anxiety Disorder. Neuropsychopharmacology, 2015, 40, 278-286.	5.4	104
48	The cognitive burden in Huntington's disease: Pathology, phenotype, and mechanisms of compensation. Movement Disorders, 2014, 29, 673-683.	3.9	116
49	Modulation of Resting-State Amygdala-Frontal Functional Connectivity by Oxytocin in Generalized Social Anxiety Disorder. Neuropsychopharmacology, 2014, 39, 2061-2069.	5.4	172
50	Using theories of delusion formation to explain abnormal beliefs in Body Dysmorphic Disorder (BDD). Psychiatry Research, 2014, 215, 599-605.	3.3	19
51	The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease. Journal of Huntington's Disease, 2014, 3, 197-207.	1.9	8
52	A comparison of executive function in Body Dysmorphic Disorder (BDD) and Obsessive-Compulsive Disorder (OCD). Journal of Obsessive-Compulsive and Related Disorders, 2013, 2, 257-262.	1.5	17
53	Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease. Psychiatry Research, 2013, 207, 118-126.	3.3	45
54	Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. International Journal of Neuropsychopharmacology, 2013, 16, 255-260.	2.1	154

#	ARTICLE	IF	CITATIONS
55	Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 687-694.	1.9	120
56	Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. International Journal of Neuropsychopharmacology, 2012, 15, 883-896.	2.1	105
57	Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 97-106.	1.9	15
58	What the Cognitive Deficits in Body Dysmorphic Disorder Tell Us about the Underlying Neurobiology: An Investigation of Three Cases. International Journal of Cognitive Therapy, 2011, 4, 21-33.	2.2	12
59	An Examination of Delusional Thinking and Cognitive Styles in Body Dysmorphic Disorder. Australian and New Zealand Journal of Psychiatry, 2010, 44, 706-712.	2.3	28
60	Executive function in body dysmorphic disorder. Psychological Medicine, 2010, 40, 1541-1548.	4.5	54
61	Augmenting serotonin neurotransmission with citalopram modulates emotional expression decoding but not structural encoding of moderate intensity sad facial emotional stimuli: an event-related potential (ERP) investigation. Journal of Psychopharmacology, 2010, 24, 1153-1164.	4.0	29
62	Oxytocin Attenuates Amygdala Reactivity to Fear in Generalized Social Anxiety Disorder. Neuropsychopharmacology, 2010, 35, 2403-2413.	5.4	427
63	Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study. Psychopharmacology, 2009, 202, 621-634.	3.1	35